TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell mediated diseases. On May 6, 2026, analyst firm H.C. Wainwright raised its price target for TG Therapeutics to $70. A price target is an analyst's projection of a stock's future price. At the time, the stock was at $39.75.
The new target suggests a potential increase, or upside, of about 76.1% from its price when the target was set. This optimism follows the company's recent performance update. For the first quarter of 2026, TG Therapeutics posted revenues of approximately $205 million, which is a significant increase from nearly $121 million a year ago.
As highlighted by Zacks, TG Therapeutics reported quarterly earnings of $0.17 per share. While this missed estimates of $0.23, it shows strong growth from $0.03 per share in the same quarter last year. The company's main product, BRIUMVI, was a key driver, contributing approximately $195 million in U.S. net revenue.
Due to this strong performance, TG Therapeutics raised its financial goals for the year. As announced by GlobeNewswire, the company now targets a total global revenue of about $925 million. It also increased its U.S. revenue forecast for BRIUMVI to a range of $885 million to $900 million for the full year.
Following the news, the stock price increased by 10.51% to $39.90. The stock's daily high of $41.24 also marked a new 52-week high, which is the highest price the stock has traded at in the past year. This reflects positive investor reaction to the company's performance and outlook.
